Gross Profit
Breakdown
Segments
Tyvaso DPIView metric
Nebulized TyvasoView metric
RemodulinView metric
OrenitramView metric
UnituxinView metric
AdcircaView metric
OtherView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $220.70M | $235.50M | $234.80M | $254.40M | $266.70M | $280.90M | $279.90M | $247.10M |
| Orenitram | $101.20M | $105.60M | $102.10M | $112.40M | $117.20M | $124.30M | $114.30M | $128.20M |
| Nebulized Tyvaso | $131.50M | $149.80M | $135.30M | $155.30M | $148.80M | $135.10M | $119.30M | $118.60M |
| Remodulin | $134.50M | $115.00M | $121.10M | $124.40M | $120.40M | $112.80M | $119.90M | $110.50M |
| Unituxin | $47.90M | $56.30M | $65.30M | $53.00M | $55.60M | $44.30M | $56.40M | $48.60M |
| Adcirca | $3.10M | $3.90M | $2.90M | $3.40M | $3.80M | $5.30M | $4.40M | $1.90M |
| Total | $637.10M | $665.80M | $660.00M | $701.90M | $711.00M | $698.60M | $686.80M | $648.10M |